“Pharmaceutical Industry China – Cutting-Edge Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges” provides you with a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 199 tables & figures within 153 pages. The Chinese biopharmaceutical market is presented as follows:

• By Company (e.g., AMOYTOP BIOTECH, BEIJING CONTINENT PHARMACEUTICALS, FUSOGEN, SHANGHAI HUAGUAN BIOCHIP, SIBIONO GENETECH, ABBOTT, ROCHE, PFIZER, GSK, NOVARTIS)
• By Therapeutic Area (e.g., Anti-infective, Cancer, Diabetes, Dementia, Depression)

A wealth of financial information is provided including:

• Company financials, sales & revenue figures – historical to Q2•2013
• China GDP, economic growth, export (bulk drug, formulations) figures
• Indian health expenditure as a function of GDP
• Growth change figures of emerging and developing countries (India, Russia, China, Brazil)
• Economic growth figures of advanced economies (USA, UK, Germany, France, Italy, Spain, Japan, Canada)
• Projected figures of strategic emerging industry GDP percentage contribution

SWOT, Economic and Business Environment specifics include:

• Key strengths, weaknesses and threats influencing leading player position within the market
• Top Five Contract Pharmaceutical Export Markets of China
• Major players within China’s leading therapeutic markets (e.g., cancer, allergy, liver disease)
• Multinational penetration into the Chinese Pharma Market
• Comprehensive product portfolios, R&D activity and pipeline therapeutics
• M&A activity and future strategies of top Chinese pharmacos
• Economic indicators, trade policy, merchandise and commercial trade statistics
• Gross Domestic Product of China, historic and projection analysis
• Chinese economic outlook in comparison to advanced economies
• Three Tier ‘Pharmerging’ Markets with Potential for Significant Growth
• Prescription drug sales distribution channels in China
• Major biogeneric products in China

This report highlights a number of significant Chinese and multinational pharmacos and gives details of their operations, products, financials and business strategy.

• Amoytop Biotech
• Active Pharmaceutical Products
• Beijing Continent Pharmaceuticals
• FusoGen Pharmaceuticals
• Shanghai Huaguan Biochip
• SiBiono GeneTech
• Abbott
• AstraZeneca
• Boehringer Ingelheim
• Eli Lilly
• GlaxoSmithKline
• Johnson & Johnson Medical
• Merck
• Novartis
• Pfizer
• Roche

Forecast projections and future growth rates are provided to give you a forthcoming perspective of this growing industry. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.

What you will gain:

• An in-depth understanding of the Chinese biopharmaceutical market and it’s environment
• Current market facts, figures and product lines of key players in the industry
• An insight into how generic therapeutics will propagate the Chinese biopharmaceutical market
• Knowledge of how the Chinese pharma market will integrate into the global healthcare market
• Information on key regulatory and government policies
• Data on levels of private and publically funded biopharma studies in China
• Strategies on how to adapt and restructure current business models to this industry

This report tackles key concerns to the Chinese biopharmaceutical market such as:

• Lack of regulatory policy and legislation
• Reimbursement schemes and payers concerns
• Funding and government sponsorship issues
• International scepticism of Chinese safety and efficacy therapeutic profiles

This report will tell you if the companies mentioned are:

• Strong, competitive players
• Pooling their resources for specific growth and therapeutic areas
• Investing strategically in R&D
• Have a history of strategic M&A activity


Benefits of Investing in our Cutting-Edge Reports:

Clients receive complementary content* with mid-level and enterprise wide licences
Post-sale complementary consultation with senior expert analyst is included
Use of tables and figures in your own reports and presentations is permitted
Each report provides straight-talking strategic analysis & sector intelligence
All reports are updated each quarter to give you the most up-to-date information

WE WANT TO MAXIMIZE YOUR BUSINESS POTENTIAL
* Subject to terms & conditions negotiated with Kelly Scientific Publications prior to sale

Table Of Contents

1.0 Summary 8
1.1 Objectives of Report 8
1.2 Scope of Study 9
1.3 Data Sources and Methodology 10
1.4 Key Findings and Observations 10
1.5 Executive Summary 11
2.0 Chronic Disease Prevalence Statistics 14
3.0 Business Environment 16
3.1 Economic Indicators, Trade Policy and Merchandise and Commercial Trade Statistics 16
3.2 Gross Domestic Product of China, Historic and Projection Analysis 18
3.3 Annual Health Expenditure in China, Historic and Projected Analysis 19
3.4 Global and Chinese Economic Outlook 2010-2013 20
3.5 Chinese Economic Outlook in Comparison to Emerging Markets and Developing Countries 21
3.6 Chinese Economic Outlook in Comparison to Advanced Economies (US, Europe) 23
4.0 Chinese Pharmaceutical Market 28
4.1 Market Overview 28
4.2 Main Players in China’s Pharmaceutical Industry 31
4.3 Anti-Allergy Drug Market 31
4.4 Asthma Drug Market 32
4.5 Benign Prostate Hyperplasia Drug Market 32
4.6 Anti-Depressant Drug market 33
4.7 Dermatitis Drug Market 35
4.8 Diabetes Drug Market 36
4.9 Hypertension Drug Market 37
4.10 Dyslipidaemia Drug Market 38
4.11 Senile Dementia Drug Market 39
4.12 Cancer Drug Market 40
4.13 Rheumatoid Arthritis Drug Market 40
4.14 Ophthalmological Drug Market 41
4.15 Liver Disease Drug Market 43
4.16 Antibiotic Drug Market 44
5.0 Government and Regulation Environment 45
5.1 12th Five Year Plan 45
5.2 Intellectual Property for Pharmaceuticals in China 47
5.3 State Food and Drug Administration (SFDA) 52
5.4 Pharmaceutical Distribution Process in China 55
6.0 China - Third Largest Pharma Market 2012 58
6.1 China - At the Forefront of Emerging Markets 58
6.2 Generic Medication Market and China 58
6.3 Novel Product Drug Development 60
6.4 Drug Development Cost and Outsourcing 62
6.5 Drug Development Case Study - Beijing Continent Pharmaceuticals 63
6.6 China’s Pharmaceutical Export Market 63
6.7 Spot Light - China Medical City Taizhou 65
7.0 Global Pharmaceutical Companies Interest in China 67
7.1 Abbott China 67
7.2 AstraZeneca China 76
7.3 Bayer China 84
7.4 Boehringer Ingelheim China 88
7.5 Eli Lilly China 92
7.6 GlaxoSmithKline China 94
7.7 Johnson and Johnson Medical China 99
7.8 Merck China 104
7.9 Novartis China 107
7.10 Novo Nordisk China 111
7.11 Pfizer China 114
7.11.1 Pfizer China RandD Centre 116
7.11.2 Pfizer China Products 116
7.11.3 Pfizer Financials 119
7.11.4 Pfizer Global 120
7.12 Roche China 121
7.13 Sanofi China 127
8.0 Chinese Pharmaceutical Companies 131
8.1 Amoytop Biotech 131
8.2 Active Pharmaceutical Products 133
8.2.1 Research and Development 134
8.2.2 Financial Information 134
8.3 Beijing Continent Pharmaceuticals 134
8.4 FusoGen Pharmaceuticals 135
8.4.1 Financial Information 136
8.5 Shanghai Huaguan Biochip 136
8.5.1 Financial Information 139
8.6 SiBiono GeneTech 139
8.6.1 Financial Information 140
8.7 Sinovac Biotech 140
8.7.1 Financial Information 142
8.7.2 New Products 147
8.7.3 Split Virion Pandemic Influenza Vaccine 147
8.7.4 RabEnd 147
8.7.5 Pipeline Portfolio 147
8.7.6 EV71 virus Vaccine 147
8.7.7 Pneumococcal Conjugate Vaccine 148
8.7.8 Pneumococcal Polysaccharide Vaccine 148
8.7.9 Varicella Vaccine 148
8.7.10 Measles, Mumps and Rubella Vaccines 148
8.7.11 Rotavirus Vaccine 148
9.0 Drivers, Restraints, Challenges and Opportunity Analysis 149
9.1 Key Drivers of the Pharmaceutical Market in China 149
9.2 Key Restraints of the Pharmaceutical Market in China 150
9.3 Challenges of the Pharmaceutical Industry in China 151
9.4 Opportunities Within BioPharma China 153

List of Tables

Table 2.1: Most Prominent Cancer Manifestations in China 15
Table 2.2: Top Fifty Diseases in China Today (non-cancer) 15
Table 2.3: Top Infectious Disease States in China Today 15
Table 3.1: World Trade Organisation Basic Indicators on China 16
Table 3.2: World Trade Organisation Trade Policy of China 16
Table 3.3: World Trade Organisation Merchandise Trade Statistics: China 17
Table 3.4: World Trade Organisation Commercial Services Trade Statistics: China 17
Table 3.5: Summary of International Monetary Fund Members’ Quota, Reserve Position, SDR Holdings, Outstanding Credit, Recent Lending Arrangements, Projected Payments Due and Monthly Historical Transactions of China 18
Table 3.6: China Statistics 18
Table 4.1: Top Global Pharma Markets 2003-2013 28
Table 4.2: Major Players in China’s Anti-Allergy Drug Market 31
Table 4.3: Major Players in China’s Asthma Drug Market 32
Table 4.4: Major Players in China’s Benign Prostate Hyperplasia (BPH) Drug Market 33
Table 4.5: Major Players in China’s Anti-Depressant Drug Market 34
Table 4.6: Prescription Dermatitis Drug Industry Sub-Markets and Associated Therapeutics 35
Table 4.7: Top Prescription Dermatitis Drugs on the Chinese Market 35
Table 4.8: Major Players in China’s Dermatitis Drug Market 35
Table 4.9: Major Players in China’s Diabetic Drug Market 37
Table 4.10: Major Players in China’s Hypertension Drug Market 38
Table 4.11: Major Players in China’s Dyslipidaemia Drug Market 38
Table 4.12: Major Players in China’s Senile Dementia Drug Market 39
Table 4.13: Major Players in China’s Cancer Drug Market 40
Table 4.14: Major Players in China’s Rheumatoid Arthritis Drug Market 41
Table 4.15: Major Players in China’s Ophthalmological Drug Market 42
Table 4.16: Major Players in China’s Liver Disease Drug Market 43
Table 4.17: Major Players in China’s Antibiotic Drug Market 44
Table 5.1: Seven Strategic Emerging Industries of China’s 12th Five Year Plan 2011-2015 45
Table 5.2: Outline of the Chinese Promotion Plan for the Implementation of the National Intellectual Property Strategy, 2012 47
Table 5.3: Challenges facing the Pharmaceutical Distribution Business in China 55
Table 5.4: Prescription Drug Sales Distribution Channels in China 55
Table 6.1: Major Biogeneric Products in China 59
Table 6.2: Imported Therapeutics with Administrative Protection in China 59
Table 6.3: Expired Proprietary Pharmaceuticals in China 60
Table 6.4: Reasons Why Multinational Companies Seek CMO’s in China 62
Table 6.5: Comparison of Clinical Trial Cost between China and the USA 63
Table 6.6: Five Functional Districts of China Medical City 65
Table 6.7: Five Key RandD and Manufacturing Areas within China Medical City 66
Table 7.1: Top Multinational Company Performance, China 67
Table 7.2: Abbott Areas of Expertise 69
Table 7.3: Abbott Key Global Products 72
Table 7.4: AbbVie (Abbott) Speciality Care Products Holding Market-Leading Positions 72
Table 7.5: Abbott China Anaesthesia Product Profile 72
Table 7.6: Abbott China Cardiovascular Product Profile 72
Table 7.7: Abbott China Vaccine Product Profile 73
Table 7.8: Abbott China Digestion Product Profile 73
Table 7.9: Abbott China HIV Product Profile 73
Table 7.10: Abbott Rheumatology HIV Product Profile 73
Table 7.11 Abbott China Gynaecological Product Profile 73
Table 7.12 Abbott China Urological Product Profile 73
Table 7.13 Abbott China Liver Disease Product Profile 73
Table 7.14 Abbott China Diagnostic Product Profile 73
Table 7.15: Abbott China Molecular Diagnostic Product Profile 74
Table 7.16: Abbott Blood Glucose Meter Product Profile 75
Table 7.17: Abbott Cardiovascular Product Profile 75
Table 7.18: Abbott Rapid Bedside Diagnostic/ Point of Care Product Profile 75
Table 7.19: Important Milestones in AstraZeneca China’s History 76
Table 7.20: AstraZeneca China Anaesthetic Range of Products 77
Table 7.21: AstraZeneca China Cardiovascular and Metabolism Range of Products 77
Table 7.22: AstraZeneca China Gastrointestinal Range of Products 77
Table 7.23: AstraZeneca China Infection Range of Products 77
Table 7.24: AstraZeneca China Neurology Range of Products 77
Table 7.25: AstraZeneca China Oncology Range of Products 77
Table 7.26: AstraZeneca China Respiratory Range of Products 77
Table 7.27: AstraZeneca Top Branded Pharmaceuticals Globally 80
Table 7.28: AstraZeneca Sales (US$ Mil) of Top Branded Pharmaceuticals Globally 80
Table 7.29: Bayer China Important Milestones 85
Table 7.30: Therapeutic Areas Covered by Bayer Healthcare Pharmaceuticals in China 86
Table 7.31: Bayer - Leading Therapeutics in China 87
Table 7.32: Bayer Top Selling Consumer Health Products 88
Table 7.33: Boehringer Ingelheim Major Products in China 88
Table 7.34: Main Therapeutic Areas of Interest to Boehringer Ingelheim China 89
Table 7.35: Global Therapeutic Pipeline, Boehringer Ingelheim 90
Table 7.36: Major Global Boehringer Ingelheim Therapeutic Products 91
Table 7.37: Eli Lilly Top Selling Global Branded Pharmaceuticals 2012-2013 ($ billion) and Percentage Change 93
Table 7.38: GlaxoSmithKline Prescription Portfolio and Indications in China 94
Table 7.39: GlaxoSmithKline Vaccine Portfolio and Indications in China 95
Table 7.40: GlaxoSmithKline Over the Counter Portfolio and Indications in China 95
Table 7.41: GlaxoSmithKline Global Pharmaceutical Sales by Therapeutic Area, FY2012-2013 97
Table 7.42: GlaxoSmithKline Global Vaccine Sales FY2012-2013 98
Table 7.43: Significant Milestones in Johnson and Johnson China History 100
Table 7.44: Johnson and Johnson Pharmaceutical Segment Sales (US$ Billion) by Therapeutic Area and Percentage Change, 2012-2013 103
Table 7.45: Merck Serono Pharmaceutical Key Therapeutic Areas in China 104
Table 7.46: Merck Serono Fertility and Infertility Therapeutic Portfolio in China 104
Table 7.47: Merck Serono Therapeutic Portfolio in China 105
Table 7.48: Merck Pharmaceutical Hong Kong Therapeutic Portfolio 105
Table 7.49: Merck Global Pharmaceutical, Animal Health and Consumer Health Sales 2012-2013 105
Table 7.50: Merck Top Ten Global Pharmaceutical Brand Sales 2012-2013 106
Table 7.51: Range of Diabetic Products from Novo Nordisk China 111
Table 7.52: QUICKFACTs - Pfizer China 115
Table 7.53: Important Milestones - Pfizer China 115
Table 7.54: Pfizer China - Range of Infectious Disease Therapeutics for Chinese Health Care Market 116
Table 7.55: Pfizer China - Range of Mental Health Products for Chinese Health Care Market 117
Table 7.56: Pfizer China - Range of Genitourinary Products for Chinese Health Care Market 117
Table 7.57: Pfizer China - Range of Endocrine Products for Chinese Health Care Market 117
Table 7.58: Pfizer China - Range of Women’s Health Products for Chinese Health Care Market 117
Table 7.59: Pfizer China - Range of Cardiovascular Disease Products for Chinese Health Care Market 117
Table 7.60: Pfizer China - Range of Oncology Products for Chinese Health Care Market 117
Table 7.61: Pfizer - Key Consumer Healthcare Global Products 118
Table 7.62: Pfizer - Key Speciality Care Global Products 118
Table 7.63: Pfizer - Key Oncology Global Products 118
Table 7.64: Pfizer - Key Global Established Products 118
Table 7.65: Pfizer - Key Innovative Products in Emerging Markets 118
Table 7.66: Pfizer - Key Animal Health Global Products 119
Table 7.67: Pfizer Product Sales with Significant Impact on Revenues 2012:2013 Comparison 119
Table 7.68: Roche Pharmaceuticals Product List in China 122
Table 7.69: Roche Global Sales (CHF Millions) by Therapeutic Area, 2012 and 2013 and Percentage Change (CER) 124
Table 7.70: Roche Pharmaceutical Division Sales from Brazil, China, India, Mexico, Russia, South Korea, Turkey, 2011, 2012, 2013 and Percentage Change (CER) 126
Table 7.71: Seven Growth Platforms of Sanofi China 127
Table 7.72: Key Therapeutic Areas of Sanofi China 128
Table 8.1: Important Milestones in Amoytop Biotech’s Development 131
Table 8.2: Amoytop Biotech - Main Objectives of Research and Development Division 132
Table 8.3: Amoytop Biotech - Panel of Recombinant Protein Therapeutics in Clinical Studies 132
Table 8.4: Amoytop Biotech Portfolio of Patented Y-Shaped Branched Pegylated Recombinant Protein Therapeutics within Clinical Investigation in China 133
Table 8.5: Current Recombinant protein therapeutics by Amoytop Biotech 133
Table 8.6: Active Pharmaceutical Product Portfolio of Amoytop Biotech 133
Table 8.7: Milestones Achieved by FusoGen Pharmaceuticals 136
Table 8.8: Research and Development Sub-groups of FusoGen Pharmaceuticals 136
Table 8.9: Shanghai Huaguan Biochip Rapid Test Portfolio 137
Table 8.10: Shanghai Huaguan Biochip Multi Drugs of Abuse Test Profile 137
Table 8.11: Shanghai Huaguan Biochip Infectious Disease Test Portfolio 137
Table 8.12: Shanghai Huaguan Biochip Diagnostic Test Portfolio 137
Table 8.13: Shanghai Huaguan Biochip Laboratory Service Portfolio 130
Table 8.14: Intracellular Functions of the Gene Therapy Agent, Gendicine by SiBiono GeneTech 139
Table 8.15: Gendicine - Potential Oncology Indications for Future Approval 140
Table 8.16: Current Human Vaccine Portfolio of Sinovac Biotech 141
Table 8.17: Important Milestones in the History of Sinovac Biotech 141
Table 8.18: Pipeline Portfolio of Sinovac Biotech 141
Table 8.19: Total Sales Figures Sinovac Biotech 2007-2012 144
Table 9.1: Key Drivers of the Pharmaceutical Market in China 149
Table 9.2: Key Restraints of the Pharmaceutical Market in China 150
Table 9.3: Key Challenges of the Pharmaceutical Market in China 151
Table 9.4: Patent Expirations of Selected Top Brand Name Therapeutics by 2020 151
Table 9.5: Leading Pharmaceutical Areas with Significant Opportunities in China 153
?
List of Figures

Figure 2.1: Proportional (%) Mortality Rate of Total Deaths in China, All Ages 14
Figure 3.1: China GDP Figures 2006-2015 19
Figure 3.2: Annual Health Expenditure in China 2006-2015 19
Figure 3.3: Global, Emerging Market and Developing Countries Economic Growth Change 2010-2013 20
Figure 3.4: Global, Emerging Market and Developing Countries and China Economic Growth Change 2010-2013 21
Figure 3.5: Global, Emerging Market and Developing Countries and Russia Economic Growth Change 2010-2013 22
Figure 3.6: Global, Emerging Market and Developing Countries and India Economic Growth Change 2010-2013 22
Figure 3.7: Global, Emerging Market and Developing Countries and Brazil Economic Growth Change 2010-2013 23
Figure 3.8: Global, US and Germany Economic Growth 2010-2013 24
Figure 3.9: US and UK Gross Domestic Product per capita Forecast 2010-2017 24
Figure 3.10: Global, France and Italy Economic Growth 2010-2013 25
Figure 3.11: France, Germay and Italy Gross Domestic Product per capita Forecast 2010-2017 25
Figure 3.12: Global, UK and Spain Economic Growth 2010-2013 26
Figure 3.13: Global, Japan and Canada Economic Growth 2010-2013 26
Figure 3.14: China, Brazil and India Gross Domestic Product per capita Forecast 2010-2017 27
Figure 4.1: The Chinese Healthcare Industry by Sector, 2011 30
Figure 5.1: Projected Figures of Strategic Emerging Industry GDP Percentage Contribution 2011-2020 46
Figure 5.2: State Drug and Food Administration, China, Application and Approval Procedure for Imported Drugs 53
Figure 5.3: State Drug and Food Administration, China, Application and Approval Procedure for Clinical Trials 54
Figure 5.4: Revenue Share (Percentage) of Major Players in Chinese Pharmaceutical Distribution Market 56
Figure 5.5: Revenue Share (Billion $) of Major Players in Chinese Pharmaceutical Distribution Market 56
Figure 6.1: Three Tier ‘Pharmerging’ Markets with Potential for Significant Growth 58
Figure 6.2: Number of Investigational New Drug Applications in China 2003-2010 60
Figure 6.3: Number of New Drug Applications in China 2003-2010 61
Figure 6.4: Current Number of Novel Therapeutics in Phase I, Phase II and Phase III Clinical Trials in China 61
Figure 6.5: Percentage of Clinical Trial Drug by Disease State 62
Figure 6.6: China’s Regional Pharmaceutical Processing Trade Export Market Share Percentage 64
Figure 6.7: Contract Amount of China’s Regional Pharmaceutical Processing Trade Export 64
Figure 6.8: Top Five Contract Pharmaceutical Export Markets of China 65
Figure 7.1: Abbott Laboratories Geographic Distribution of Revenue -USA, Established and Emerging Markets 69
Figure 7.2: Abbott Laboratories Established and Emerging Revenue Share (%) 2012-2015 70
Figure 7.3: Abbott - Business Specialization Strategy 2012: Diversified Medical Products and Research-Based Pharmaceuticals 70
Figure 7.4: Abbott Diversified Medical Product Portfolio 71
Figure 7.5: AstraZeneca Sales Revenue (US$ Millions) in China, 2010-2013 79
Figure 7.6: AstraZeneca Global Revenue (Billions) by Geographic Area: USA, Western Europe, Emerging Markets 2012 79
Figure 7.7: AstraZeneca Cardiovascular Product (Atacand, Crestor, Seloken/Toprol-XL) Global Sales 2010-2012 81
Figure 7.8: AstraZeneca Gastrointestinal Product (Nexium) Global Sales 2010-2012 81
Figure 7.9: AstraZeneca Infection Product (Synagis) Global Sales 2010-2012 82
Figure 7.10: AstraZeneca Neuroscience Product (Seroquel-IR, -XR) Global Sales 2010-2012 82
Figure 7.11: AstraZeneca Oncology Product (Zoladex) Global Sales 2010-2012 83
Figure 7.12: AstraZeneca Respiratory/Inflammation Product (Pulmicort, Symbicort) Global Sales 2010-2012 83
Figure 7.13: Boehringer Ingelheim Oncology Compounds in Development 91
Figure 7.14: GlaxoSmithKline Total Sales, Pharmaceutical, Vaccine and Consumer Healthcare Sales 2012-2013 (£ Billions) 96
Figure 7.15: GlaxoSmithKline Global Pharmaceutical Sales by Therapeutic Area, 2012-2013 97
Figure 7.16: GlaxoSmithKline Global Vaccine Sales by Therapeutic Area, 2012-2013 98
Figure 7.17: GlaxoSmithKline Global Sales by Geographic Region - USA, Europe, Emerging Markets, Japan, 2012-2013 99
Figure 7.18: Johnson and Johnson Pharmaceutical Segment Sales (US$ Billion) by Therapeutic Area, 2012-2013 103
Figure 7.19: Novartis International Sales (%) by Geographic Region, 2012-2013 109
Figure 7.20: Novartis International Sales (US$ Millions) by Geographic Region, 2012-2013 110
Figure 7.21: Novo Nordisk Total China Sales 2009-2013 113
Figure 7.22: Novo Nordsk Total Diabetes Care Market Sales Performance (DKK Millions) China 2010-2013 113
Figure 7.23: Novo Nordisk Diabetes Care (NovoRapid/NovoLog, NovoMix/NovoLog Mix, Levemir, Modern Insulin, Human Insulin, Victoza) Sales Performance (DKK Millions) China 2010-2013 114
Figure 7.24: Business Sectors - Pfizer China 116
Figure 7.25: Roche Total Global Sales (CHF Millions) 2012-2013 125
Figure 7.26: Roche Global Sales (CHF Millions) by Therapeutic Area, 2012-2013 125
Figure 7.27: Roche Pharmaceutical Division Emerging Market Total Sales 2012-2013 126
Figure 7.28: Roche Pharmaceutical Division Sales from Brazil, China, India, Mexico, Russia, South Korea, Turkey, 2012-2013 127
Figure 7.29: Sanofi Geographic Market Share (%) - Emerging Markets, USA and Western Europe 2012 129
Figure 7.30: Sanofi Geographic Market Share (%) -China, Russia and USA 2012 130
Figure 8.1: FusoGen Pharmaceuticals Product Pipeline and Clinical Trial Progression 135
Figure 8.2: Shanghai Huaguan Biochip Serial Analysis of Gene Expression (SAGE) Service 138
Figure 8.3: Total Sales Figures Sinovac Biotech 2007-2012 143
Figure 8.4: Percentage of Sales Attributed to Healive Vaccine, 2009-2012 144
Figure 8.5: Reported Sales of Healive Vaccine, 2009-2012 145
Figure 8.6: Reported Sales of Bilive Vaccine, 2009-2012 145
Figure 8.7: Reported Sales of Anflu Vaccine, 2009-2012 146
Figure 8.8: Reported Sales of Panflu Vaccine, 2009-2011 146


View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

DNA Vaccines: Technologies and Global Markets

DNA Vaccines: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • July 2014
  • by BCC Research

This BCC Research study determines the specific applications and global market demand for DNA vaccine products over a five-year period from 2014 to 2019. High growth and market potential segments of the ...

Detailed I/E report of Carbendazim export analysis

Detailed I/E report of Carbendazim export analysis

  • $ 5 400
  • Industry report
  • July 2014
  • by CCM International Limited

Carbendazim export analysis will help clients indentify export situation of technical and formulations with exclusive research methods, to offer not only the target products' export volume, price, time, ...

Global Foot Care Products Industry

Global Foot Care Products Industry

  • $ 4 950
  • Industry report
  • July 2014
  • by Global Industry Analysts

This report analyzes the worldwide markets for Foot Care Products in US$ by the following Product Segments: Devices, and Medication. The report provides separate comprehensive analytics for the US, Canada, ...


2 Companies

Company Profiles

Johnson and Johnson

United States

Boeing Co.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.